GlobeNewswire by notified

Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate

Share
  • Bavarian Nordic’s non-adjuvanted COVID-19 vaccine candidate, ABNCoV2 (100μg), demonstrated a strong boosting effect, increasing the existing levels of SARS-CoV-2 neutralizing antibodies against the Wuhan variant by 2-40-fold depending on the initial levels of antibodies
  • The large boosting effect of ABNCoV2 elevated the neutralizing antibodies to levels reported to be highly efficacious (>90%) against SARS-CoV-21
  • A similar fold increase was observed for all SARS-CoV-2 variants tested (Wuhan, Alpha, Beta and Delta) following the booster vaccination with ABNCoV2
  • The vaccine was well-tolerated, with no serious adverse events reported
  • These initial results confirm the potential of ABNCoV2 to function as a universal COVID-19 booster vaccine
  • The Company’s management will host a conference call tomorrow at 2 pm CET (8 am EST) to discuss the results

COPENHAGEN, Denmark, December 5, 2021 – Bavarian Nordic A/S (OMX: BAVA), a fully integrated vaccines company, announced today positive topline results from a Phase 2 clinical trial of its COVID-19 vaccine candidate, ABNCoV2.

ABNCoV2 Phase 2 trial results
One hundred and three (103) subjects 18 years and older (23% above 65 years) that had been previously vaccinated with mRNA (67%) or adenoviral (32%) COVID-19 vaccines were enrolled and received a single booster vaccination with ABNC0V2 (100μg). At enrolment, the majority (≥57%) of all subjects either had no detectable neutralizing antibodies and/or were below the levels that could be quantified and the average neutralizing antibody titers against all SARS-CoV-2 variants tested were at levels reported to provide decreased levels of protection from COVID-191. One (1) week post vaccination with ABNCoV2, a 2-34-fold increase in the levels of neutralizing antibodies against the Wuhan SARS-CoV2 variant was observed and peaked at two (2) weeks with a 2-40-fold increase depending on the initial antibody levels. However, all subjects, irrespective of whether they initially had very low, or high neutralizing titers were boosted to absolute antibody levels reported to be associated with a very high efficacy (>90%) against SARS-CoV21.

The same trend in terms of the fold-increases post the booster with ABNCoV2 was also observed for all other SARS-CoV2 variants tested, namely Alpha, Beta and Delta.

ABNCoV2 was well tolerated with no serious adverse events reported. The most frequent observations were local injection site reactions that resolved shorty after vaccination.

Enrolment continues in the second seropositive group, receiving a single 50μg dose of ABNCoV2 and a seronegative group receiving two 100μg doses of ABNCoV2.

Paul Chaplin, President and CEO of Bavarian Nordic, commented: “We are very pleased to report positive top-line results for our COVID-19 vaccine candidate, confirming the perfect profile as a non-adjuvanted universal booster vaccine. I am encouraged to see that ABNCoV2 boosted the levels of immunity to those associated with a high efficacy against COVID-19 and this was the case whether there was a low or high initial neutralizing antibody level. These results highlight the urgent need for an improved vaccine providing a more robust and long-lived level of protection”.
About the ABNCoV2 Phase 2 trial
The Phase 2 trial is planned to enroll a total of 210 healthy adult volunteers divided into three groups, of which results from the first group are being reported today:

  • Individuals (n=90, actual=103) with existing immunity against SARS-CoV-2 (seropositive), from prior vaccination (mRNA and Adeno) or SARS-CoV-2 infection, receiving a single 100μg dose of ABNCoV2.
  • Individuals (n=90) with existing immunity against SARS-CoV-2 (seropositive), from prior vaccination (mRNA and Adeno) or SARS-CoV-2 infection, receiving a single 50μg dose of ABNCoV2.
  • Individuals (n=30) with no prior vaccination or SARS-CoV-2 infection (seronegative), receiving two 100μg doses of ABNCoV2.

Topline results for the first group confirmed ABNCoV2’s ability to significantly boost antibody titers to levels associated with a very high degree of efficacy. High neutralizing antibody titers were demonstrated against all SARS-CoV-2 variants tested, including Delta.

Results from the two other study groups are expected during the first quarter of 2022. In parallel, Bavarian Nordic is also preparing for a Phase 3 trial of ABNCoV2, expected to be initiated in the first half of 2022 pending final feedback from the regulatory authorities.

Conference call and webcast
The management of Bavarian Nordic will host a conference call tomorrow, Monday, December 6, 2021, at 2 pm CET (8 am EST) to discuss the Phase 2 results, which will be followed by a Q&A session. A listen-only version of the call can be accessed via https://www.bavarian-nordic.com/investor/events.aspx?event=6437. To join the Q&A session, use one of the following dial-in numbers: Denmark: +45 32 72 04 17, UK: +44 (0) 844 481 9752, USA: +1 646-741-3167. Participant code is 4569358.

About ABNCoV2
ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac using their proprietary capsid virus like particle (cVLP) technology. Bavarian Nordic has licensed the global commercialization rights to the vaccine and has assumed the responsibility for further clinical development towards licensure.

ABNCoV2 has shown to be highly immunogenic in relevant preclinical models inducing a durable and highly protective response from a COVID-19 challenge. Topline data from the Phase 2 trial has confirmed the ability to significantly boost antibody titers as previously demonstrated in preclinical and Phase 1 clinical trials. The data confirms the potential of ABNCoV2 to boost antibody titers against the Wuhan, Alpha, Beta and Delta SARS-CoV2 variants.

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 38 / 2021




1 P. B. Gilbert et al., Science 10.1126/science.abm3425 (2021)


Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Alation Welcomes Tim Harford OBE as Keynote Speaker at revAlation in London18.8.2022 09:00:00 CEST | Press release

World renowned behavioural economist joins The Very Group CDO to keynote Alation’s industry conference LONDON, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Alation Inc., the leader inenterprise data intelligence solutions, today announced that revAlation, its flagship industry conference for data professionals across EMEA, will take place on 4th October and 5th October at County Hall, London. The two-day event will feature data networking opportunities, data training, and keynotes from award winning economist, journalist, and broadcaster Tim Harford, and Chief Data Officer of The Very Group, Steve Pimblett. Tim Harford is a bestselling author of books about economics and data, and the writer of the award-winning Financial Times column, The Undercover Economist. Harford will keynote the event and discuss how to use data and economics in everyday life. Steve Pimblett is the Chief Data Officer at leading UK and Ireland online retailer, The Very Group. Pimblett is an experienced data professional, ha

Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)18.8.2022 08:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 18 August 2022 at 9:30 am Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the voting rights attached to Sampo A shares (ISIN: FI009003305) owned directly or indirectly by BlackRock, Inc. (USA tax ID 32-0174421) and its funds decreased on 16 August 2022 below five (5) per cent of Sampo plc’s total voting rights. Sampo's share capital comprises 533,261,351 shares, of which 533,061,351 are A shares and 200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 534,061,351. Total positions of BlackRock, Inc and its funds subject to the notification: % of shares and voting rights (total of A)% of shares and voting rights through financial instruments (total of B)Total of both in % (A+B)Resultin

Systemair's Interim Report for the first quarter will be presented on August 2518.8.2022 08:00:00 CEST | Press release

Press Release, 18 August 2022 Systemair ABs (NASDAQ OMX Stockholm: SYSR) Interim Report Q1 for the financial year 2022/23 will be published at 13:00 CET on August 25, 2022. A telephone conference will be held at 13:30 CET on August 25, 2022. The report will be presented by Roland Kasper, CEO, and Anders Ulff, CFO. In order to participate in the telephone conference: Call 010-884 8016 alternative international call +44 20 3936 2999 and enter code 539199 minutes before start. The presentation will be published on group.systemair.com For further information contact: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair AB, SE-739 30 Skinnskatteberg, Sweden, +46 222 440 00, www.systemair.com Systemair in brief Systemair is a leading ventilation company with operations in 52 countries in Europe, North America, the Middle East, Asia, Australia and Africa. The Company had sales of SEK 9.6 billion in the 2021/22 financial year and today employs approximately 6,700

Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review18.8.2022 08:00:00 CEST | Press release

The TENDU interim safety results from nine patients show no safety concernsTrial extended to enroll up to three additional patients at the highest dose levelTENDU designed to evaluate the Tetanus-Epitope Targeting (TET)-platform in patients with prostate cancer Oslo, 18August 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, has completed treatment of three patients at the highest dose cohort in the phase I TENDU trial without any safety concerns. Based on these results, the company plans to enroll up to three additional patients at the highest dose level. The Drug Safety Monitoring Board, a group of experts set up to monitor patient safety during a clinical trial, found no safety concerns in any of the three dose cohorts. A total of nine patients have now been treated; three at each dose level (40 mcg, 400 mcg and 960 mcg). Ultimovacs plans to enroll up to three additional patients at the highest dose level (960 mcg) pro

Systemairs rapport för det första kvartalet presenteras den 25 augusti18.8.2022 08:00:00 CEST | Pressemelding

Pressmeddelande 18 augusti 2022 Systemair ABs (NASDAQ OMX Stockholm: SYSR) delårsrapport Q1 för räkenskapsåret 2022/23 kommer att offentliggöras kl. 13:00 CET den 25 augusti 2022. En telefonkonferens arrangeras kl. 13:30 CET den 25 augusti 2022. Rapporten presenteras av Roland Kasper, CEO, samt Anders Ulff, CFO. För att delta i telefonkonferensen: Ring 010-884 8016 alt. internationellt +44 20 3936 2999 och uppge kod 539199 minuter före start. Presentationen publiceras på group.systemair.com För ytterligare information kontakta: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair AB, 739 30 Skinnskatteberg, 0222-440 00, www.systemair.com Systemair i korthet Systemair är ett ledande ventilationsföretag med verksamhet i 52 länder i Europa, Nordamerika, Mellanöstern, Asien, Australien och Afrika. Bolaget omsatte 9,6 miljarder kronor räkenskapsåret 2021/22 och har idag cirka 6 700 anställda. Sedan grundandet av Systemair 1974 har bolaget uppvisat positiva rör